Urea Cream Shortage: What Providers and Prescribers Need to Know in 2026

Prescribing urea topical in 2026 is more complicated than it should be. Despite no active FDA-declared national shortage, your patients are frequently unable to fill their urea prescriptions — and they're coming back to your office frustrated. This guide provides a clear clinical picture of the current urea market, what's discontinued, what's available, and how to ensure your patients can actually obtain their treatment.

Current Urea Availability Status (2026)

There is no active FDA shortage listing for urea topical as of 2026. Multiple manufacturers — including Acella Pharmaceuticals and Laser Pharmaceuticals — continue to produce generic urea products in various strengths. However, the market is highly fragmented:

Over 60 brand names historically marketed; a significant portion are discontinued

Concentrations range from 2% to 50% across dozens of formulations (cream, lotion, gel, foam, ointment, solution, shampoo, nail stick)

Retail pharmacy stocking is inconsistent — especially for concentrations above 40%

Key Brand Discontinuations to Know

Prescriptions written for discontinued brands will not be filled. The following products have been discontinued (marked "[DSC]" in current drug databases):

Cerovel (urea cream)

MeTopic (urea 41% cream)

Umecta Mousse and Umecta Nail Film

Rea Lo 40 (urea 40% cream)

Uredeb, Uremez-40, Uresol, Urealac Nail

When prescribing, verify that the brand you're writing for is currently available. Prescribing generically ("urea 40% cream" rather than a specific brand) gives the pharmacist flexibility to dispense an available equivalent.

Prescribing Recommendations for Better Patient Access

Write generically: Prescribe "urea [X]% [formulation]" rather than a specific brand to allow pharmacist substitution. This is critical for high-strength products like 40%, 45%, and 47%.

Approve DAW-1 exceptions cautiously: Brand-name-only prescriptions for urea are rarely clinically justified — generic equivalents at the same concentration are bioequivalent for topical use.

Consider 90-day supply for chronic conditions: For patients with ichthyosis, keratoderma, psoriasis, or other long-term skin conditions, a 90-day mail-order supply avoids repeated fill challenges.

Document therapeutic necessity for PA: Some insurance plans require prior authorization for prescription-strength urea (40%+). Document the diagnosis (ICD-10 code), prior OTC treatment trials, and clinical response when submitting PA requests.

Therapeutic Alternatives When Urea Is Unavailable

When urea is unavailable or when specific concentrations are not accessible, the following alternatives are well-supported by clinical evidence:

Ammonium lactate 12% (Lac-Hydrin): RCT data shows comparable efficacy to 5% salicylic acid/10% urea for foot xerosis. Available by Rx; generic AmLactin 12% available OTC. Well-tolerated in most patients.

Salicylic acid 6%–17%: Effective for calluses, corns, psoriatic plaques, and actinic keratosis pretreatment. Available OTC and by Rx. Caution with large body surface area application.

Lactic acid 10%–12%: First-line choice by most dermatologists for keratosis pilaris (43.63% of practitioners per survey data). 10% lactic acid showed 66% KP lesion reduction after 12 weeks in clinical studies.

Tretinoin 0.025%–0.1% (for severe ichthyosis): Topical retinoids promote deeper cellular turnover and can be used when urea is unavailable for ichthyosis vulgaris or similar keratinization disorders.

How medfinder Helps Your Patients Find Urea

Rather than sending patients on a manual pharmacy hunt, consider referring them to medfinder. medfinder contacts pharmacies near your patient's location on their behalf to check which ones have the specific urea product in stock. The patient receives a text with results — no hold music, no repeated explanations to pharmacy staff.

See also our provider guide to helping patients find urea in stock for a step-by-step workflow.